Bisphosphonates/denosumab interaction
- PDF / 169,168 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 31 Downloads / 178 Views
1 XS
Atypical femoral fractures: case report In a study of 19 patients, a female patient [age not stated] was described, who developed atypical femoral fractures (AFF) following concomitant administration of denosumab and unspecified bisphosphonate for hypophosphatasia [route, dosage, duration of treatment to reaction onset and outcome not stated]. The female patient, who had hypophosphatasia, received unspecified bisphosphonate previously. Subsequently, she started receiving treatment with denosumab. However, she developed atypical femoral fractures. Later, it was confirmed that denosumab and her previous exposure to the unspecified bisphosphonate were associated with atypical femoral fractures; as denosumab might have prolonged the bisphosphonate retention in her skeleton, which led to the development of atypical femoral fractures. Lefever E, et al. Hypophosphatasia in Adults: Clinical Spectrum and Its Association With Genetics and Metabolic Substrates. Journal of Clinical Densitometry 23: 340-348, 803519423 No. 3, Sep 2020. Available from: URL: http://doi.org/10.1016/j.jocd.2018.12.006
0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Dec 2020 No. 1833
Data Loading...
